Skip to main content Accessibility help
Hostname: page-component-99c86f546-66nw2 Total loading time: 0.515 Render date: 2021-12-05T21:43:09.878Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Chapter 10 - An Introduction to Sellar Masses

Published online by Cambridge University Press:  24 December 2018

Michael Wilkinson
Dalhousie University, Nova Scotia
S. Ali Imran
Dalhousie University, Nova Scotia
Get access
Clinical Neuroendocrinology
An Introduction
, pp. 171 - 184
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Babic, N, Yeo K-T, J, Hannoush, Z C & Weiss, R E. (2017). Endocrine testing protocols: hypothalamic pituitary adrenal axis.
Abu Dabrh, A, Asi, N, Farah, W et al. (2015). Radiotherapy vs. radiosurgery in treating patients with acromegaly: systematic review and meta-analysis. Endocr Pract 21, 943956.CrossRefGoogle ScholarPubMed
Al-Dahmani, K, Mohammad, S, Imran, F et al. (2016). Sellar masses: an epidemiological study. Can J Neurol Sci 43, 291297.CrossRefGoogle ScholarPubMed
Beck-Peccoz, P, Persani, L, Faglia, G. (1992). Glycoprotein hormone α-subunit in pituitary adenomas. Trends Endocr Metab 3, 4145.CrossRefGoogle ScholarPubMed
Beck-Peccoz, P, Lania, A, Beckers, A, Chatterjee, K & Wemeau, J-L. (2013). European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Europ Thyroid J 2, 7682.CrossRefGoogle ScholarPubMed
Bonneville, J-F. (2016). Magnetic resonance imaging of pituitary tumors. Front Horm Res 45, 97120.CrossRefGoogle ScholarPubMed
Burrell, S, Hebb, A L O, Imran, S A, Mishra, A, Mawko, G & Clarke, D B. (2017). Visualization of 90Yttrium colloid within a cystic craniopharyngioma using PET/CT/MRI fusion. Can J Neurol Sci 44, 192193.CrossRefGoogle ScholarPubMed
Carmichael, J D, Bonert, V S, Nuño, M, Ly, D & Melmed, S. (2014). Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocr Metab 99, 18251833.CrossRefGoogle ScholarPubMed
Chanson, P & Brochier, S. (2005). Non-functioning pituitary adenomas. J Endocr Invest 28 (11 Suppl Int), 9399.Google ScholarPubMed
Colao, A, Ferone, D, Marzullo, P & Lombardi, G. (2004). Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25, 102152.CrossRefGoogle ScholarPubMed
Dolecek, T A, Propp, J M, Stroup, N E & Kruchko, C. (2012). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14 (Suppl 5), 149.CrossRefGoogle ScholarPubMed
Frieze, T W, Mong, D P & Koops, M K. (2002). “Hook effect” in prolactinomas: case report and review of literature. Endocr Pract 8, 296303.CrossRefGoogle ScholarPubMed
Gadelha, M R, Bronstein, M D, Brue, T et al. (2014). Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocr 2, 875884.CrossRefGoogle ScholarPubMed
Greenman, Y, Tordjman, K, Osher, E et al. (2005). Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocr 63, 3944.CrossRefGoogle ScholarPubMed
Guttenberg, K B, Mayson, S E, Sawan, C et al. (2016). Prevalence of clinically silent corticotroph macroadenomas. Clin Endocr 85, 874880.CrossRefGoogle ScholarPubMed
Heck, A, Ringstad, G, Fougner, SL et al. (2012). Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocr 77, 7278.CrossRefGoogle ScholarPubMed
Hukin, J, Steinbok, P, Lafay-Cousin, L et al. (2007). Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 109, 21242131.CrossRefGoogle ScholarPubMed
Imran, S A, Fleetwood, I G, O’Connell, C M et al. (2009). Outcome of stereotactic radiotherapy for patients with uncontrolled acromegaly. Can J Neurol Sci 36, 468474.CrossRefGoogle ScholarPubMed
Imran, S A, Tiemensma, J, Kaiser, S M et al. (2016). Morphometric changes correlate with poor psychological outcomes in patients with acromegaly Eur J Endocr 174, 4150.CrossRefGoogle ScholarPubMed
Imran, S A, Yip, C E, Papneja, N et al. (2016). Analysis and natural history of pituitary incidentalomas. Europ J Endocr 175, 19.CrossRefGoogle ScholarPubMed
Imran, S A, Shankar, J, Hebb, A L O, Croul, S E & Clarke, D B. (2017). Radiological growth patterns of prolactinomas and nonfunctioning adenomas. Can J Neurol Sci 44, 508513.CrossRefGoogle ScholarPubMed
Jacob, J J & Bevan, J S. (2014). Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long? Clin Endocr 81, 812817.CrossRefGoogle ScholarPubMed
Katznelson, K, Laws, E R, Melmed, S et al. (2014). Acromegaly: an endocrine society clinical practice guideline. J Clin Endocr Metab 99, 39333951.CrossRefGoogle Scholar
Kinoshita, Y, Tominaga, A, Usui, S et al. (2016). The long-term recurrence of Rathke’s cleft cysts as predicted by histology but not by surgical procedure. J Neurosurg 125, 10021007.CrossRefGoogle Scholar
Lucas, J W & Zada, G. (2012). Imaging of the pituitary and parasellar region. Semin Neurol 32, 320331.Google ScholarPubMed
Melmed, S. (2006). Acromegaly. N Engl J Med 355, 25582573.CrossRefGoogle ScholarPubMed
Minniti, G, Clarke, E, Scaringi, C, Enrici, R M. (2016). Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother 21, 370378.CrossRefGoogle ScholarPubMed
Newell-Price, J, Trainer, P, Perra, L, Wass, J, Grossman, A & Besser, M A. (1995). A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocr 43, 545550.CrossRefGoogle Scholar
Nieman, L K, Biller, B M, Findling, J W et al. (2008). The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocr Metab 93, 15261540.CrossRefGoogle Scholar
Papanicolaou, D A, Yanovski, J A, Cutler, G B Jr., Chrousos, G P & Nieman, L K. (1998). A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states. J Clin Endocr Metab 83, 11631167.Google ScholarPubMed
Petersenn, S, Beckers, A, Ferone, D et al. (2015). Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Europ J Endocr 172, R227R239.CrossRefGoogle ScholarPubMed
Samson, S L, Hamrahian, A H & Ezzat, S. (2015). Clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract 21, 14271435.CrossRefGoogle ScholarPubMed
Sandret, L, Maison, P, Chanson, P. (2012). Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocr Metab 96, 13271335CrossRefGoogle Scholar
Sharma, S T, Nieman, L K & Feelders, R A. (2015). Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol 7, 281293.Google ScholarPubMed
Tjörnstrand, A, Gunnarsson, K, Evert, M et al. (2014).The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocr 171, 519526.CrossRefGoogle ScholarPubMed
van der Lely, A J, Biller, B M, Brue, T et al. (2012). Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocr Metab 97, 15891597.CrossRefGoogle ScholarPubMed
Vaninetti, N, Clarke, D B, Zwicker, D A et al. (2018). A comparative population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses. Endocr Connect 7, 768776.CrossRefGoogle ScholarPubMed
Verhelst, J, Abs, R, Maiter, D et al. (1999). Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocr Metab 84, 25182522.CrossRefGoogle ScholarPubMed
Webster, J, Pisreflli, G, Polli, A, Ferrari, CI, Ismail, I & Scanlon, M F. (1994). A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New Engl J Med 331, 904909.CrossRefGoogle ScholarPubMed
Woo, Y S, Isidori, A M, Wat, W Z et al. (2005). Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocr Metab 90, 49634969.CrossRefGoogle ScholarPubMed
Yip, C E, Stewart, S A, Imran, F et al. (2013). The role of morning basal serum cortisol in assessment of hypothalamic pituitary-adrenal axis. Clin Invest Med 36, E216E222.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats